Prevalence of dyslipidaemia in statin-treated patients in Ireland: Irish results of the DYSlipidaemia International Study (DYSIS)

Irish Journal of Medical Science

Volumn 180, Issue 2, 2011, Pages 343-349

  Horgan, S ^a   Crowley, J ^b   Feely, J ^c   McAdam, B ^d   Shanahan, E ^e   Vaughan, C ^f  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c ST JAMES S HOSPITAL   (Ireland)

^d BEAUMONT HOSPITAL   (Ireland)

^e TRINITY COLLEGE DUBLIN   (Ireland)

^f MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Cardiovascular risk; Cross sectional study; DYSIS; Dyslipidaemia; HDL C; LDL C; Lipids; Statin; Triglycerides

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; EUROPE; FEMALE; HIGH RISK PATIENT; HUMAN; IRELAND; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRESCRIPTION; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IRELAND; MALE; MIDDLE AGED; PREVALENCE; TRIGLYCERIDES;

EID: 79955625860     PISSN: 00211265     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11845-011-0702-8     Document Type: Article

References (17)

1. Allender S, Scarborugh P, Peto V et al (2008) European cardiovascular disease statistics, 2008 edition. British Heart Foundation Research Group & Health Economics Research Centre, pp 11-14
2. Central Statistics Office, Cork, Ireland. Deaths from principal causes in the years 1998 to 2006. http://www.cso.ie/statistics/principalcausesofdeath.htm
3. Activity in Acute Public Hospitals in Ireland 2008: Annual Report of the Hospital In-Patient Enquiry (HIPE) scheme. Economic and Social Research Institute (ESRI) 2010, pp 109-120. http://www.esri.ie
4. Unal B, Critchly J, Capewell S (2004) Explaining the decline in coronary heart disease mortality in England and Wales between 1981 and 2000. Circulation 109:1101-1107
5. Kelleher C, Nic Gabhainn S, Friel S et al (2003) The National Health and Lifestyle Surveys (Phase 2), Survey of Lifestyle, Attitudes and Nutrition (SLAN) & The Irish Health Behaviour in School-Aged Children Survey (HBSC). Department of Health and Children, Dublin, pp 59-66
6. Making Diabetes Count. A systematic approach to estimating population prevalence on the island of Ireland in 2005. Published by the Institute of Public Health of Ireland, April 2006, pp 39-44. http://www.publichealth.ie
7. Baigent C, Keech A, Kearney PM, Cholesterol Treatment Trialists' (CTT) Collaborators et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267-1278
8. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R et al (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117-125
9. Barter PJ, Puranik R, Rye KA (2007) New insights into the role of HDL as an anti-inflammatory agent in the prevention of cardiovascular disease. Curr Cardiol Rep 9:493-498 (Pubitemid 350081421)
10. McBride P (2008) Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 10:386-390
11. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 28:2375-2414 (Epub 2007 Aug 28)
12. Roberts WC (1997) The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 80:106-107
13. Grundy SM, Cleeman JI, Merz CN et al (2004) Implications of recent clinical trial fro the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227-239 (Pubitemid 38924592)
14. Kotseva K, Wood D, De Backer G, EUROASPIRE Study Group et al (2009) Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373:929-940
15. Bruckert E, Baccara-Dinet M, Eschwege E (2007) Low HDL-cholesterol is common in European type 2 diabetic patients receiving treatment for dyslipidaemia: data from a pan-European survey. Diabet Med 24:388-391 (Pubitemid 46452407)
16. Goff DC Jr, Bertoni AG, Kramer H et al (2006) Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 113:647-656
17. Kotseva K, Wood D, De Backer G, on behalf of the EUROASPIRE Study Group et al (2009) Euroaspire III Survey. Eur J Cardiovasc Prev Rehabil 16:121-137